NOVARTIS INDIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,066 INR | +1.18% |
|
+0.85% | +37.89% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 4B 47.89M | Sales 2023 | 3.79B 45.36M | Capitalization | 13.96B 167M |
|---|---|---|---|---|---|
| Net income 2022 | -37M -443K | Net income 2023 | 1.03B 12.38M | EV / Sales 2022 | 2.41 x |
| Net cash position 2022 | 4.92B 58.96M | Net cash position 2023 | 5.33B 63.83M | EV / Sales 2023 | 2.28 x |
| P/E ratio 2022 |
-392
x | P/E ratio 2023 |
13.5
x | Employees | 67 |
| Yield 2022 |
1.69% | Yield 2023 |
1.77% | Free-Float | 27.17% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.18% | ||
| 1 week | +0.85% | ||
| Current month | +3.01% | ||
| 1 month | +2.11% | ||
| 3 months | +16.63% | ||
| 6 months | +59.44% | ||
| Current year | +37.89% |
1 week
1 045.00
1 080.00
1 month
991.001 080.00
Current year
768.601 224.00
1 year
599.951 224.00
3 years
554.001 224.00
5 years
420.051 224.00
10 years
420.051 224.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shilpa Joshi
DFI | Director of Finance/CFO | - | 22-04-30 |
Bhavna Gupta
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 20-06-21 | |
| Chairman | - | 08-07-31 | |
Sandra Martyres
BRD | Director/Board Member | 71 | 16-04-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1,066 | +1.18% | 14,104 |
| 24-05-09 | 1,054 | -1.42% | 11,034 |
| 24-05-08 | 1,069 | +0.32% | 9,146 |
| 24-05-07 | 1,066 | +0.33% | 30,601 |
| 24-05-06 | 1,062 | +0.45% | 23,376 |
Delayed Quote Bombay S.E., May 10, 2024 at 06:17 am EDT
More quotes
Novartis India Limited is an India-based company that is engaged in the business of trading of pharmaceuticals. The Company's portfolio of medicines addresses various therapeutic needs, such as cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India. In the bone and pain therapeutic area its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +37.89% | 315M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- NOVARTIND Stock